6-TERT-BUTYL-2-(3-METHYLUREIDO)-4-OXO-4H-CHROMENE-3-CARBOXAMIDE


Source	Gaulton A, Kale N, van Westen GJ, Bellis LJ, Bento AP, Davies M, Hersey A, Papadatos G, Forster M, Wege P, Overington JP. A large-scale crop protection bioassay data set. Sci Data. 2015 Jul 7;2:150032. Read more ...


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	DHBZEIWPDQGTLM-UHFFFAOYSA-N
Smiles	CNC(=O)NC1=C(C(=O)N)C(=O)c2cc(ccc2O1)C(C)(C)C
InChI	InChI=1S/C16H19N3O4/c1-16(2,3)8-5-6-10-9(7-8)12(20)11(13(17)21)14(23-10)19-15(22)18-4/h5-7H,1-4H3,(H2,17,21)(H2,18,19,22)

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C16H19N3O4
Molecular Weight	317.34
AlogP	1.55
Hydrogen Bond Acceptor	4.0
Hydrogen Bond Donor	3.0
Number of Rotational Bond	3.0
Polar Surface Area	110.51
Molecular species	NEUTRAL
Aromatic Rings	1.0
Heavy Atoms	23.0

Assay Description	Organism	Bioactivity
In vivo fungicidal activity against Rhizoctonia solani in rice seedlings assessed as control of sheath blight disease at 500 ppm by curative foliar treatment	Rhizoctonia solani	100.0 %
Fungicidal activity against Rhizoctonia solani by agar dilution method	Rhizoctonia solani	100.0 ug.mL-1
Fungicidal activity against Magnaporthe salvinii by agar dilution method	Magnaporthe salvinii	0.78 ug.mL-1
Fungicidal activity against Bipolaris oryzae by agar dilution method	Bipolaris oryzae	100.0 ug.mL-1
Fungicidal activity against Magnaporthe oryzae by agar dilution method	Magnaporthe oryzae	0.78 ug.mL-1

Cross References

Resources	Reference
ChEMBL	CHEMBL2288720
PubChem	14151544
SureChEMBL	SCHEMBL8752324

CONTENTS


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).